Welcome to our dedicated page for Scienture Holdings SEC filings (Ticker: SCNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D milestones, FDA language, and detailed patient-service revenue make Scienture Holdings’ filings dense even for seasoned analysts. Tracking when executives file Form 4s just days before material 8-K announcements can feel like piecing together clinical trial data and accounting footnotes at the same time.
Stock Titan solves that problem. Our AI converts every Scienture Holdings quarterly earnings report 10-Q filing, annual report 10-K simplified summary, and Scienture Holdings 8-K material events explained into plain-English takeaways you can read in minutes. Need Scienture Holdings insider trading Form 4 transactions or Scienture Holdings Form 4 insider transactions real-time? They appear instantly, alongside AI-highlighted context such as upcoming drug approval dates. We also surface the numbers you search for most—R&D spend, specialty-drug margins, and reimbursement trends—so understanding Scienture Holdings SEC documents with AI becomes effortless.
Whether you’re reviewing a Scienture Holdings proxy statement executive compensation before voting, scanning a Scienture Holdings earnings report filing analysis for segment growth, or setting alerts for Scienture Holdings executive stock transactions Form 4, you’ll find the complete archive here, updated the moment EDGAR posts. No more page-by-page hunts: just clear answers to "Scienture Holdings SEC filings explained simply" and a streamlined view of compliance data investors actually use.
Scoggin-affiliated investors report a small passive stake in Scienture Holdings Inc. The filing discloses that Scoggin International Fund Ltd., Scoggin Management LP, Scoggin GP LLC and individuals Curtis Schenker and Craig Effron each beneficially own 150,000 shares of Scienture common stock, representing 0.01% of the 16,131,180 shares outstanding cited in the filing. The reporting persons state the holdings were not acquired to influence control of the issuer and identify the relationships among the entities: Scoggin GP LLC is the general partner of Scoggin Management LP, which manages Scoggin International Fund Ltd., and Messrs. Schenker and Effron are co-managing members. Exhibits include a joint filing agreement and an Item 8 statement.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 1,075,000 shares of Scienture Holdings, Inc. common stock, representing 5.55% of the outstanding class based on 19,356,180 shares cited in the issuer's prospectus supplement. The filing states the fund has sole voting and sole dispositive power over these shares and includes a standard disclaimer noting two directors of the fund, David Feldman and Joel Arber, may be deemed to have an interest but disclaim beneficial ownership except to the extent of pecuniary interest.
Prospectus supplement summary: The document presents terms of a securities offering and related company disclosures. The placement agent fee is stated as $0.08 per share totaling $270,900, and the proceeds before expenses are shown as $1.12 per share totaling $3,599,100. The filing lists common shares outstanding at various points: 126,683,845, 127,894,248, and 130,828,731. A historical net tangible book value per share is disclosed as $(1.27). The company notes anticipated capitalization changes from the conversion of secured convertible promissory notes, conversion of Series B preferred stock, and potential exercise of 2,270,672 options (weighted average exercise price $1.22) and 238,594 warrants (weighted average exercise price $19.02). The filing also states that Scienture, LLC relies on third‑party CMOs for all manufacturing and does not own manufacturing facilities.
Scienture Holdings, Inc. (f/k/a TRxADE Health) reported a weak operating quarter with minimal revenue and mounting losses while consolidating a major acquisition. Total assets were $104.3 million, driven primarily by $76.4 million of acquired product technology intangibles and $21.37 million of goodwill from the July 25, 2024 Scienture acquisition. One product, SCN-102, received regulatory approval in March 2025 and commercialization is projected to begin in 2025.
Operating results show revenues of $10,258 for the six months ended June 30, 2025 and a net loss from continuing operations of $9.78 million for the same period (quarter loss $6.72 million). Cash on hand was $15,391 at June 30, 2025 and the company discloses substantial doubt about its ability to continue as a going concern. The company completed divestitures of legacy subsidiaries for a $5.0 million promissory note and maintains convertible debentures and a derivative liability related to a $3.33 million Arena financing.
Scienture Holdings, Inc. (f/k/a TRxADE Health) filed an amended Form D to update its private placement details.
- Offering: Equity securities under Reg D Rule 506(b) & Securities Act §4(a)(5).
- Size: $3.0 million; $1.715 million (≈57%) sold since first sale on 18 Jul 2025; $1.285 million remains.
- Investors: 8 participants; minimum investment $50,000.
- Compensation: Finalis Securities LLC to receive $35,000 sales commission; no finder’s fees.
- Use of proceeds: General working capital; no payments to executives/directors.
- Issuer profile: Delaware corporation, principal office Commack, NY; operates in Pharmaceuticals; revenue range not disclosed; offering expected to close within one year.
The amendment confirms meaningful investor traction and continued capital needs as the company works toward its $3 million goal.
FAQ
What is the current stock price of Scienture Holdings (SCNX)?
What is the market cap of Scienture Holdings (SCNX)?
